AB-FUBINACA is an indazole-based synthetic cannabinoid (CB) with 10-fold greater affinity for the central CB₁ receptor (K_i = 0.9 nM) than that of JWH 018 .^1,2 AB-FUBINACA was first synthesized by Pfizer, Inc. as a potent CB₁ receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA  in illegal herbal products.^1,2 AB-FUBINACA 2-fluorobenzyl isomer differs structurally from AB-FUBINACA by having a fluorine at the 2 position of a benzyl ring rather than a fluorine at the 4 position of a phenyl ring. This compound binds CB₁ with a K_i value of 4.69.² This product is intended for research and forensic applications

≥98%